Literature DB >> 24905803

Tim-3 polymorphism downregulates gene expression and is involved in the susceptibility to ankylosing spondylitis.

Mingfei Wang1, Bin Ji, Jian Wang, Xiangyu Cheng, Qiang Zhou, Junjie Zhou, Chengfu Cao, Qunfeng Guo.   

Abstract

Ankylosing spondylitis (AS) is a chronic inflammatory disorder primarily affecting the sacroiliac joints and the spine. T-cell immunoglobulin- and mucin-domain-containing molecule 3 (TIM-3) has been established as a negative regulatory molecule that plays a critical role in controlling inflammation. Studies have shown that polymorphisms in TIM-3 gene may be associated with inflammatory diseases. The current study investigated the association between polymorphisms in the TIM-3 gene and susceptibility to AS, and it examined the effects of these polymorphisms on gene expression. Two polymorphisms in TIM-3 -574G/T and +4259T/G polymorphisms were identified by polymerase chain reaction-restriction fragment length polymorphism in 282 AS patients and 298 healthy controls. Results showed that frequency of the TIM-3 -574GT genotype was significantly increased in cases than in controls (Odd ratio [OR]=2.50, 95% confidence interval [CI]: 1.39-4.48, p=0.002). Similarly, TIM-3 -574T allele revealed a positive association with the disease (OR=2.39, p=0.002). The TIM-3 +4259T/G polymorphism did not show any correlation with AS. We further evaluated TIM-3 mRNA and protein levels in CD4(+) T cells, CD8(+) T cells, and monocytes from subjects carrying different TIM-3 genotypes. Results revealed that subjects carrying polymorphic -574GT genotype had significantly lower TIM-3 mRNA and protein levels in CD4(+) T cells, CD8(+) T cells, and monocytes than those with wild-type GG genotype. These data suggest that TIM-3 polymorphism is associated with increased susceptibility to AS possibly by downregulating gene expression.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24905803     DOI: 10.1089/dna.2014.2456

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  10 in total

1.  TIM-3 Genetic Variations Affect Susceptibility to Osteoarthritis by Interfering with Interferon Gamma in CD4+ T Cells.

Authors:  Shufeng Li; Yanjun Ren; Dayong Peng; Zhen Yuan; Shiying Shan; Huaqiang Sun; Xinfeng Yan; Hong Xiao; Guang Li; Haihan Song
Journal:  Inflammation       Date:  2015-10       Impact factor: 4.092

2.  Downregulation of T cell immunoglobulin and mucin protein 3 in the pathogenesis of intracranial aneurysm.

Authors:  Hai-Feng Zhang; Ming-Guang Zhao; Guo-Biao Liang; Chun-Yong Yu; Zhi-Qing Li; Xu Gao
Journal:  Inflammation       Date:  2015-02       Impact factor: 4.092

Review 3.  Tim-3, Lag-3, and TIGIT.

Authors:  Nicole Joller; Vijay K Kuchroo
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

Review 4.  Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.

Authors:  Ana C Anderson; Nicole Joller; Vijay K Kuchroo
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

5.  TIM-3 Rs10515746 (A/C) and Rs10053538 (C/A) Gene Polymorphisms and Risk of Multiple Sclerosis.

Authors:  Esmat Yaghoobi; Saeed Abedian; Omid Babani; Maryam Izad
Journal:  Iran J Public Health       Date:  2016-05       Impact factor: 1.429

6.  Polymorphisms in TIM-3 and breast cancer susceptibility in Chinese women: A case-control study.

Authors:  Zheng Wang; Xinghan Liu; Xijing Wang; Tie Chong; Shuai Lin; Meng Wang; Xiaobin Ma; Kang Liu; Peng Xu; Yanjing Feng; Zhijun Dai
Journal:  Oncotarget       Date:  2016-07-12

Review 7.  Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets.

Authors:  Hwei-Fang Tsai; Ping-Ning Hsu
Journal:  J Biomed Sci       Date:  2017-05-25       Impact factor: 8.410

Review 8.  The Potential Role of Genetics, Environmental Factors, and Gut Dysbiosis in the Aberrant Non-Coding RNA Expression to Mediate Inflammation and Osteoclastogenic/Osteogenic Differentiation in Ankylosing Spondylitis.

Authors:  Hsien-Tzung Liao; Chang-Youh Tsai; Chien-Chih Lai; Song-Chou Hsieh; Yi-Syuan Sun; Ko-Jen Li; Chieh-Yu Shen; Cheng-Han Wu; Cheng-Hsun Lu; Yu-Min Kuo; Tzu-Hao Li; Chung-Tei Chou; Chia-Li Yu
Journal:  Front Cell Dev Biol       Date:  2022-01-20

Review 9.  Immune Checkpoints as Therapeutic Targets in Autoimmunity.

Authors:  Christopher Paluch; Ana Mafalda Santos; Consuelo Anzilotti; Richard J Cornall; Simon J Davis
Journal:  Front Immunol       Date:  2018-10-08       Impact factor: 7.561

10.  TIM-3 rs1036199 polymorphism increases susceptibility to autoimmune diseases: evidence based on 4200 subjects.

Authors:  Rongzeng Liu; Xing Wang; Xiafei Chen; Shengnan Wang; Heqian Zhang
Journal:  Biosci Rep       Date:  2018-11-23       Impact factor: 3.840

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.